Switch theme
Sign up to access all valuation multiples
3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.
2006
5.6K+
LTM Revenue $1.6B
LTM EBITDA $697M
$5.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
3SBio has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $697M.
In the most recent fiscal year, 3SBio achieved revenue of $1.2B and an EBITDA of $422M.
3SBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 3SBio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $999M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $697M | XXX | $422M | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $582M | XXX | $349M | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $465M | XXX | $267M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $189M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 3SBio's stock price is HKD 19 (or $2).
3SBio has current market cap of HKD 44.3B (or $5.7B), and EV of HKD 41.9B (or $5.3B).
See 3SBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.3B | $5.7B | XXX | XXX | XXX | XXX | $0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 3SBio has market cap of $5.7B and EV of $5.3B.
3SBio's trades at 4.6x EV/Revenue multiple, and 12.7x EV/EBITDA.
Equity research analysts estimate 3SBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
3SBio has a P/E ratio of 13.2x.
See valuation multiples for 3SBio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBIT | 10.0x | XXX | 15.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.2x | XXX | 21.2x | XXX | XXX | XXX |
| EV/FCF | 15.5x | XXX | 18.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial3SBio's last 12 month revenue growth is 17%
3SBio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
3SBio's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
3SBio's rule of X is 85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 3SBio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 71% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 53% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
3SBio acquired XXX companies to date.
Last acquisition by 3SBio was XXXXXXXX, XXXXX XXXXX XXXXXX . 3SBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 3SBio founded? | 3SBio was founded in 2006. |
| Where is 3SBio headquartered? | 3SBio is headquartered in Hong Kong. |
| How many employees does 3SBio have? | As of today, 3SBio has 5.6K+ employees. |
| Who is the CEO of 3SBio? | 3SBio's CEO is Dr. Jing Lou, M.D.,PhD. |
| Is 3SBio publicy listed? | Yes, 3SBio is a public company listed on HKG. |
| What is the stock symbol of 3SBio? | 3SBio trades under 01530 ticker. |
| When did 3SBio go public? | 3SBio went public in 2015. |
| Who are competitors of 3SBio? | Similar companies to 3SBio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of 3SBio? | 3SBio's current market cap is $5.7B |
| What is the current revenue of 3SBio? | 3SBio's last 12 months revenue is $1.6B. |
| What is the current revenue growth of 3SBio? | 3SBio revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of 3SBio? | Current revenue multiple of 3SBio is 3.6x. |
| Is 3SBio profitable? | Yes, 3SBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 3SBio? | 3SBio's last 12 months EBITDA is $697M. |
| What is 3SBio's EBITDA margin? | 3SBio's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of 3SBio? | Current EBITDA multiple of 3SBio is 8.3x. |
| What is the current FCF of 3SBio? | 3SBio's last 12 months FCF is $375M. |
| What is 3SBio's FCF margin? | 3SBio's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of 3SBio? | Current FCF multiple of 3SBio is 15.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
